R-METRIX: Critical Evaluation of FDG-Inspired Metabolic Targeting and Molecular Resonance for Heterogeneous, Evolving, and Immune-Evasive Cancers
R-METRIX: Exploring Metabolic Targeting and Molecular Resonance for Difficult-to-Treat Cancers Cancer remains a major therapeutic challenge, particularly when tumors develop genetic heterogeneity, continuously evolve, acquire treatment resistance, and suppress or evade immune responses. R-METRIX is a conceptual research framework developed by Alkhaleeli BioAI LLC that investigates a potential physical approach to cancer treatment inspired by fluorodeoxyglucose (FDG) metabolic trapping and molecular resonance. The proposed concept explores whether a chemically defined, metabolically targeted compound could accumulate in relevant cancer cells and produce a measurable mechanical response when exposed to external energy. The research focuses on three major challenges: 1. Tumor Heterogeneity: Cancer cells within the same tumor may contain different mutations and exhibit different biological characteristics. 2. Cancer Evolution and Treatment Resistance: Tumors can acquire additional genetic and functional changes, allowing some cancer-cell populations to survive existing therapies. 3. Immune Suppression and Evasion: Cancer cells may exploit biological mechanisms that prevent effective immune recognition and elimination. Unlike mutation-specific or immune-dependent approaches, R-METRIX investigates a potential physical mechanism that would not necessarily depend on identifying every individual cancer mutation or directly stimulating T-cell activity. The manuscript critically evaluates three conceptual molecular architectures, glucose-related transport, intracellular retention, molecular resonance, mechanical energy transfer, and biological selectivity. AI-assisted computational research, mathematical modeling, and scientific literature analysis are used to examine the feasibility and limitations of the proposed concept. Scientific Conclusion: R-METRIX remains an investigational hypothesis. Its proposed integrated mechanism, tumor selectivity, safety, and therapeutic effectiveness have not been experimentally demonstrated. Further research must establish chemical identity, cellular transport, intracellular retention, and mechanically attributable energy transfer before therapeutic relevance can be assessed. Research Objective: To investigate whether combining metabolic targeting and controlled physical energy transfer could contribute to future treatment strategies for heterogeneous, evolving, treatment-resistant, and immune-evasive cancers. Author: Rami M. Alkhaleeli Affiliation: Alkhaleeli BioAI LLC, Oklahoma, United States Version: 1.2 | November 18, 2026 Research Field: Computational Oncology, Molecular Biophysics, Cancer Therapeutics, and AI-Assisted Drug Discovery.
Authors
- Alkhaleeli Rami (ORCID: https://orcid.org/0009-0004-0210-9015)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5281/zenodo.24358562
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- preprint